Bill
National Health Amendment (Pharmaceutical Benefits Transparency and Cost Recovery) Bill 2021
lapsed, as at 2022-07-25. Health portfolio.
- Sponsor
- Not recorded
- Portfolio
- Health
Recorded stages
- introduced — 2021-03-17
- second reading — 2021-03-17
- other — 2022-07-25
Divisions
No divisions recorded. Most questions are decided on the voices; this does not establish that a bill was unopposed.
Plain-language summary
Written by a model from the explanatory memorandum; not the record, as at 2021-03-17.
The bill would allow the Department of Health to publish more information about pharmaceutical benefits and simplify how it recovers costs.
It would put existing publication practices into law and let fees for services be set through a disallowable legislative instrument instead of regulations.
The bill would also let the Department charge separate fees for entering into, managing, varying and renewing deed arrangements, starting when those costs occur.
- Creates a statutory basis for publishing PBAC agendas, meeting outcomes, public summary documents and Medicine Status Website information.
- Replaces the current regulation-based cost recovery system with a disallowable legislative instrument for setting fees and costs.
- Allows separate fee categories for deed-related activities so costs can be recovered at the time the Commonwealth incurs them.
The Department of Health, pharmaceutical companies, and industry stakeholders involved in the Pharmaceutical Benefits Scheme.
Sources
em
billhome